Apprehension concerning Fed’s approach to interest rate cuts in ’24 triggered a downturn for biotech sector in March. BB Biotech’s investment level is close to upper limit (114%, limit: 115%), reflecting the management team’s optimistic outlook for the biotech sector. A devaluation of the Swiss Franc against major currencies like the USD provided a significant boost to BB Biotech’s portfolio in Q1/24. Share can be bought at 3% discount to NAV.

https://research.sebgroup.com/corporate/reports/127013

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.